Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy?

There is currently no FDA-approved disease-modifying therapy for diabetic peripheral neuropathy (DPN). Nerve conduction velocity (NCV) is an established primary endpoint of disease-modifying therapies in DPN and clinical trials have been powered with an assumed decline of 0.5 m/s/year. This paper so...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Bazz, Dalal Y., Nelson, Andrew J., Burgess, Jamie, Petropoulos, Ioannis N., Nizza, Jael, Marshall, Anne, Brown, Emily, Cuthbertson, Daniel J., Marshall, Andrew G., Malik, Rayaz A., Alam, Uazman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947384/
https://www.ncbi.nlm.nih.gov/pubmed/35328284
http://dx.doi.org/10.3390/diagnostics12030731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947384/
https://www.ncbi.nlm.nih.gov/pubmed/35328284
http://dx.doi.org/10.3390/diagnostics12030731

Ejemplares similares